Who are Cuvposa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Northera, Vesicare, Evoxac, Detrol, Provocholine, Atrovent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glycopyrronium-bromide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Cuvposa — Competitive Intelligence Brief

Cuvposa (GLYCOPYRRONIUM BROMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Metabolic.

marketed Anticholinergic Muscarinic acetylcholine receptor M1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Cuvposa (GLYCOPYRRONIUM BROMIDE) — Shionogi. Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cuvposa TARGET	GLYCOPYRRONIUM BROMIDE	Shionogi	marketed	Anticholinergic	Muscarinic acetylcholine receptor M1	1961-01-01
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Vesicare	SOLIFENACIN	Astellas Pharma	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Evoxac	CEVIMELINE	Cosette	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	2000-01-01
Detrol	TOLTERODINE	Upjohn	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Provocholine	METHACHOLINE	Methapharm	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	1986-01-01
Atrovent	IPRATROPIUM		marketed	Anticholinergic	Muscarinic acetylcholine receptor M1	1986-01-01

Recent regulatory actions (last 90 days)

2026-02-23 — Atrovent · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-16 — Cuvposa · 11278683 · US
2028-10-11 — Cuvposa · 8479730 · US
2028-10-20 — Cuvposa · 8182838 · US
2028-12-07 — Cuvposa · 9265900 · US
2029-02-26 — Cuvposa · 10940110 · US
2030-05-28 — Cuvposa · 8324266 · US
2030-05-28 — Cuvposa · 10716753 · US
2030-05-28 — Cuvposa · 9463161 · US
2030-05-28 — Cuvposa · 9415009 · US
2030-05-28 — Cuvposa · 8808713 · US
2030-05-28 — Cuvposa · 8703806 · US
2030-10-30 — Cuvposa · 9789270 · US
2031-03-17 — Cuvposa · 8815258 · US
2032-09-01 — Cuvposa · 9168556 · US
2033-05-16 — Cuvposa · 9604018 · US
2035-09-14 — Cuvposa · 10376661 · US
2036-11-12 — Cuvposa · 10688518 · US
2036-12-07 — Cuvposa · 10744277 · US
2038-05-10 — Cuvposa · 11331442 · US
2038-10-25 — Cuvposa · 11110054 · US
2038-10-25 — Cuvposa · 10456354 · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cuvposa — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-bromide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab